The Effect of the Addition of Dronedarone to, Versus Increase of, Existing Conventional Rate Control Medication on Ventricular Rate During Paroxysmal or Persistent Atrial Fibrillation.

Trial Profile

The Effect of the Addition of Dronedarone to, Versus Increase of, Existing Conventional Rate Control Medication on Ventricular Rate During Paroxysmal or Persistent Atrial Fibrillation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Dronedarone (Primary) ; Beta-adrenergic receptor antagonists; Calcium channel antagonists; Digoxin
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms AFRODITE
  • Sponsors Sanofi
  • Most Recent Events

    • 09 Nov 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 09 Nov 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 09 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top